Could One Test Replace Multiple Leukemia Assays? - Takeaways - MDSpire

Could One Test Replace Multiple Leukemia Assays?

Researchers assess whether long-read transcriptome sequencing can streamline B-ALL diagnostics

  • May 29, 2026

  • 3 min

Share

  • 1

    A new long-read sequencing approach may improve detection of fusion oncogenes in pediatric B-cell acute lymphoblastic leukemia (B-ALL).

  • 2

    The study evaluated a tool called FUSILLI, which analyzes long-read RNA sequencing data for identifying gene fusions in B-ALL.

  • 3

    FUSILLI demonstrated the highest sensitivity for detecting clinically relevant fusions in high-depth sequencing samples.

  • 4

    The study found that approximately 10 million reads per sample may be needed for optimal fusion detection performance.

  • 5

    Long-read whole-transcriptome sequencing could support comprehensive molecular profiling of pediatric B-ALL, reducing the need for multiple assays.

Original Source(s)

Could One Test Replace Multiple Leukemia Assays?

  • May 29, 2026

Related Content

Why We Made a Mobile Digital Pathology Lab

Todd R. Minnigh and his team created ScanVan to address a problem with rare cancer diagnosis that had a particularly personal significance

Preclinical Study in Mice Addresses a Question: Should RAS Inhibitors Be Given Preemptively?

With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer, the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research ...

FDA Approves Durvalumab Plus BCG for High-Risk NMIBC

On May 28, 2026, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adult patients wi...